600196 复星医药
已收盘 11-20 15:00:00
资讯
新帖
简况
复星医药(600196)披露H股股份购回进展,11月20日股价下跌1.98%
证券之星 · 11-20 18:36
复星医药(600196)披露H股股份购回进展,11月20日股价下跌1.98%
股市必读:复星医药新发布《复星医药H股公告-翌日披露报表》
证券之星 · 11-20 01:24
股市必读:复星医药新发布《复星医药H股公告-翌日披露报表》
复星医药:暂无新增质押公司股份计划
证券之星 · 11-19 17:33
复星医药:暂无新增质押公司股份计划
复星医药:二级市场价格波动受多种因素综合影响
证券之星 · 11-19 17:33
复星医药:二级市场价格波动受多种因素综合影响
复星医药(02196)11月18日耗资约2694.38万港元回购180.7万股
智通财经 · 11-18
复星医药(02196)11月18日耗资约2694.38万港元回购180.7万股
阿尔茨海默病口服药迎关键进展 复星医药(02196)“重算”AD市场边界
智通财经 · 11-18
阿尔茨海默病口服药迎关键进展 复星医药(02196)“重算”AD市场边界
复星医药(02196)11月17日斥资约4438.98万港元回购300万股
智通财经 · 11-17
复星医药(02196)11月17日斥资约4438.98万港元回购300万股
4亿元押注明星药,数据存变数!复星医药股价跌6.81%
东方财富网 · 11-17
4亿元押注明星药,数据存变数!复星医药股价跌6.81%
复星医药(600196.SH)董事长提议2.5亿元至5亿元回购公司A股股份
智通财经 · 11-17
复星医药(600196.SH)董事长提议2.5亿元至5亿元回购公司A股股份
复星医药(02196)AH股齐跌超8% AR1001 III期总体人群未达统计学显著性
金吾财讯 · 11-17
复星医药(02196)AH股齐跌超8% AR1001 III期总体人群未达统计学显著性
复星医药(600196.SH):口服在研药物AR1001 III期临床试验数据公布 尚未行使独家选择权
智通财经 · 11-17
复星医药(600196.SH):口服在研药物AR1001 III期临床试验数据公布 尚未行使独家选择权
中国复星医药:口服在研药物AR1001用于治疗早期阿尔茨海默病的全球多中心III期临床试验相关数据显示,在总体人群中,治
格隆汇 · 11-17
中国复星医药:口服在研药物AR1001用于治疗早期阿尔茨海默病的全球多中心III期临床试验相关数据显示,在总体人群中,治
股市必读:复星医药新发布《复星医药关于控股子公司药品获新纳入国家医保目录的提示性公告》
证券之星 · 11-17
股市必读:复星医药新发布《复星医药关于控股子公司药品获新纳入国家医保目录的提示性公告》
复星医药(02196): FXR0906 注射液用于治疗高甘油三酯血症于中国境内启动 II 期临床试验
智通财经 · 11-16
复星医药(02196): FXR0906 注射液用于治疗高甘油三酯血症于中国境内启动 II 期临床试验
复星医药(600196.SH)控股子公司药品SRT-003-1获临床试验批准
智通财经 · 11-16
复星医药(600196.SH)控股子公司药品SRT-003-1获临床试验批准
复星医药:控股子公司药品HLX105获临床试验批准
格隆汇 · 11-16
复星医药:控股子公司药品HLX105获临床试验批准
复星医药:多款药品新纳入国家医保目录
格隆汇 · 11-15
复星医药:多款药品新纳入国家医保目录
复星医药(02196)11月13日斥资2458.98万港元回购148.55万股
智通财经 · 11-13
复星医药(02196)11月13日斥资2458.98万港元回购148.55万股
复星医药:计划回购H股不超过港币10亿元
证券之星 · 11-13
复星医药:计划回购H股不超过港币10亿元
复星医药:二级市场股价受公司经营、行业发展、市场情绪、宏观环境等多重因素影响
证券之星 · 11-13
复星医药:二级市场股价受公司经营、行业发展、市场情绪、宏观环境等多重因素影响
加载更多
公司概况
公司名称:
上海复星医药(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1998-08-07
主营业务:
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务,并通过参股国药控股覆盖到医药商业领域。公司的主要产品是注射用曲妥珠单抗(中国境内商品名:汉曲优)及曲妥珠单抗原液、汉利康(利妥昔单抗注射液)、斯鲁利单抗注射液(中国境内商品名:汉斯状)、奥康泽(奈妥匹坦帕洛诺司琼胶囊)、奕凯达(阿基仑赛注射液)、一心坦(沙库巴曲缬沙坦钠片)、汉贝泰(贝伐珠单抗注射液)、汉奈佳(马来酸奈拉替尼片)、倍稳(盐酸凯普拉生片)、珮金(拓培非格司亭注射液)、苏可欣(马来酸阿伐曲泊帕片)、汉达远(阿达木单抗注射液)、普瑞尼(普托马尼片)、达希斐(注射用A型肉毒毒素)、复可舒(抗人T细胞兔免疫球蛋白)、复迈宁(芦沃美替尼片)、欧泰乐(阿普米司特片)、地舒单抗注射液、复妥宁(枸橼酸伏维西利胶囊)、汉倍优(帕妥珠单抗注射液)、万缇乐(盐酸替那帕诺片)、旁必福(盐酸依特卡肽注射液)。
发行价格:
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":20.3,"timestamp":1795158000000,"preClose":20.71,"halted":0,"volume":19709295,"delay":0,"changeRate":-0.0198,"floatShares":2118000000,"shares":2670000000,"eps":1.3162,"marketStatus":"已收盘","change":-0.41,"latestTime":"11-20 15:00:00","open":20.46,"high":20.5,"low":20.14,"amount":399000000,"amplitude":0.0174,"askPrice":20.3,"askSize":37,"bidPrice":20.29,"bidSize":6,"shortable":0,"etf":0,"ttmEps":1.3162,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":5,"adr":0,"adjPreClose":20.71,"symbolType":"stock","openAndCloseTimeList":[[1795138200000,1795145400000],[1795150800000,1795158000000]],"highLimit":22.78,"lowLimit":18.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.08,"roa":"--","peRate":15.423188,"roe":"5.42%","epsLYR":1.27,"committee":-0.12298,"marketValue":54210000000,"turnoverRate":0.0093,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-11-23。","hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":14.39,"timestamp":1795162109004,"preClose":15.11,"halted":0,"volume":3408679,"delay":0,"premium":"-39.56"},"floatMarketCap":43005000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2684557951","title":"复星医药(600196)披露H股股份购回进展,11月20日股价下跌1.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2684557951","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684557951?lang=zh_cn&edition=full","pubTime":"2026-11-20 18:36","pubTimestamp":1795170983,"startTime":"0","endTime":"0","summary":"截至2026年11月20日收盘,复星医药报收于20.3元,较前一交易日下跌1.98%,最新总市值为542.1亿元。该股当日开盘20.46元,最高20.5元,最低20.14元,成交额达3.99亿元,换手率为0.93%。该等股份拟持作库存股份。本次购回在联交所进行,占购回前已发行股份的0.36%。本次购回后30日内不得发行新股或出售库存股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026112000032197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1593","BK0012","BK0060","BK0187","600196","BK0028","BK1191","BK1515","BK0175","BK0196","BK0183","BK0096","02196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684290668","title":"股市必读:复星医药新发布《复星医药H股公告-翌日披露报表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2684290668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684290668?lang=zh_cn&edition=full","pubTime":"2026-11-20 01:24","pubTimestamp":1795109056,"startTime":"0","endTime":"0","summary":"复星医药H股公告-翌日披露报表上海复星医药(集团)股份有限公司于2026年11月19日购回1,845,000股H股股份,每股购回价介乎港币14.9元至15.1元之间,总代价为港币27,768,960元。该等股份拟持作库存股份。本次购回后30日内不得发行新股或出售库存股份。如涉及重大业务进展等事项,公司将根据上市地监管要求,及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026112000000686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","BK0187","BK1593","BK0012","BK0060","BK0239","BK1191","600196","BK1515","BK0183","BK0188","BK0096","BK0196","BK0028","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684922821","title":"复星医药:暂无新增质押公司股份计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2684922821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684922821?lang=zh_cn&edition=full","pubTime":"2026-11-19 17:33","pubTimestamp":1795080807,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药(600196)11月19日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,董秘,贵司大股东复星科技持股8.9亿股,质押5.6亿股,质押比达高60%,贵司股价如此大跌,是否有质押平仓风险?复星医药回复:投资者您好!经向控股股东征询,截至回复日,其暂无新增质押公司股份计划、亦无因质押被强制平仓的情形;如其后续有质押情况变动,将根据相关法律法规要求及时履行告知义务。公司也将密切关注控股股东股份质押的进展情况,并按法律法规和股票上市地规则的要求,及时公告。感谢您对公司的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111900031131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK1191","BK0187","02196","BK0239","BK0183","BK0188","BK0028","BK0096","BK0175","BK0060","BK1515","BK1593","600196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684815922","title":"复星医药:二级市场价格波动受多种因素综合影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2684815922","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684815922?lang=zh_cn&edition=full","pubTime":"2026-11-19 17:33","pubTimestamp":1795080793,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药11月19日在投资者关系平台上答复投资者关心的问题。二级市场价格波动受多种因素综合影响,其中还包括市场情绪、资金偏好等。如涉及重大业务进展等事项,公司将根据上市地监管要求,及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111900031115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK1593","BK1515","BK0188","02196","BK0012","BK0239","BK0060","BK0096","BK1191","BK0183","BK0028","600196","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684496116","title":"复星医药(02196)11月18日耗资约2694.38万港元回购180.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2684496116","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684496116?lang=zh_cn&edition=full","pubTime":"2026-11-18 17:30","pubTimestamp":1794994217,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)公布,2026年11月18日耗资约2694.38万港元回购180.7万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1525059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK1191","BK1593","BK1515","BK0175","BK0188","02196","BK0028","BK0096","BK0060","BK0012","BK0187","BK0196","600196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684953924","title":"阿尔茨海默病口服药迎关键进展 复星医药(02196)“重算”AD市场边界","url":"https://stock-news.laohu8.com/highlight/detail?id=2684953924","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684953924?lang=zh_cn&edition=full","pubTime":"2026-11-18 09:43","pubTimestamp":1794966207,"startTime":"0","endTime":"0","summary":"《中国阿尔茨海默病报告2026》显示,2023年我国AD及各类痴呆患病人数已达2029.9万例,每年新发病例347.7万例;2025年中国学者在AAIC发布的研究显示,轻度认知障碍与轻度AD合计占比高达52.5%。近期有机构预测,AD治疗市场将在2030年前后达到百亿美元级别。“对复星医药而言,市场需要重新计算的,是整个早期AD人群的规模,以及一款口服药在其中的触达边界。”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1524803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK0188","BK1593","BK0183","BK0096","BK0175","BK0060","BK0187","BK0028","BK1191","BK1515","BK0196","BK0239","02196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684603045","title":"复星医药(02196)11月17日斥资约4438.98万港元回购300万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2684603045","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684603045?lang=zh_cn&edition=full","pubTime":"2026-11-17 17:21","pubTimestamp":1794907288,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,于2026年11月17日该公司斥资约4438.98万港元回购300万股,回购价格为每股14.49至15.01港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1524410.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1191","BK0012","BK1515","BK0060","02196","BK1593","600196","BK0175","BK0187","BK0096","BK0196","BK0188","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684770608","title":"4亿元押注明星药,数据存变数!复星医药股价跌6.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2684770608","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684770608?lang=zh_cn&edition=full","pubTime":"2026-11-17 16:45","pubTimestamp":1794905100,"startTime":"0","endTime":"0","summary":"复星医药半年前以6000万美元(约4亿人民币)押注的阿尔茨海默病创新药物三期临床试验出炉,相关数据并不完美。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202611173932906739.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202611173932906739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK0187","BK0188","BK1593","02196","BK0196","600196","BK0183","BK0239","BK1191","BK0096","BK0175","BK0028","BK0012","BK0060","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684670089","title":"复星医药(600196.SH)董事长提议2.5亿元至5亿元回购公司A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2684670089","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684670089?lang=zh_cn&edition=full","pubTime":"2026-11-17 16:32","pubTimestamp":1794904342,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)发布公告,公司董事长陈玉卿提议公司以集中竞价交易方式回购公司境内上市人民币普通股(A股)。回购资金总额不低于2.5亿元且不超过5亿元(均含本数)。回购资金来源为公司自有资金及/或自筹资金。回购股份可由公司用于未来发行可转债的转股、实施股权激励计划及/或员工持股计划等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1524328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03188","BK0183","83188","BK0187","02823","02196","600196","BK0175","02843","07233","BK0012","159982","02822","BK0028","BK0196","BK1610","BK0096","BK0188","02827","BK1191","82822","82846","BK1147","03130","399300","BK1515","BK1593","02846","83130","BK0060","82843","BK0239","82823"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684620665","title":"复星医药(02196)AH股齐跌超8% AR1001 III期总体人群未达统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=2684620665","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684620665?lang=zh_cn&edition=full","pubTime":"2026-11-17 10:29","pubTimestamp":1794882561,"startTime":"0","endTime":"0","summary":"金吾财讯 | 复星医药 盘中股价下挫8.21%,暂报14.86港元,成交额1.13亿港元。根据口头报告,该III期临床试验相关数据显示:在单药治疗人群1中,该临床试验的主要终点指标CDR-SB达到统计学显著性,达成主要疗效目标;但在总体人群中,治疗组较安慰剂组展现出了组间差异、尚未达到统计学显著性。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1996179","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1593","BK1515","02196","BK0028","600196","BK0060","BK0196","BK0175","BK0187","BK1191","BK0188","BK0012","BK0096","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684962460","title":"复星医药(600196.SH):口服在研药物AR1001 III期临床试验数据公布 尚未行使独家选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2684962460","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684962460?lang=zh_cn&edition=full","pubTime":"2026-11-17 08:50","pubTimestamp":1794876631,"startTime":"0","endTime":"0","summary":"美国东部时间2026年11月16日,口服在研药物AR1001用于治疗早期阿尔茨海默病的全球多中心III期临床试验顶线数据结果在美国波士顿举行的第19届阿尔茨海默病临床试验大会上以口头报告形式首次公布。截至本公告日期,复星医药产业尚未就上述全球新增许可区域行使独家选择权,潜在许可尚未达成。复星医药产业将进一步分析和评估与AR1001相关的研究数据,以决定是否行使前述选择权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1524115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","ELIL","LLYX","BK0183","BK0028","BK0188","BK0239","02196","ELIS","BK0012","BK0187","BK0096","LLII","BK0196","BK0060","BK0175","BK1515","BK1593","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684621611","title":"中国复星医药:口服在研药物AR1001用于治疗早期阿尔茨海默病的全球多中心III期临床试验相关数据显示,在总体人群中,治","url":"https://stock-news.laohu8.com/highlight/detail?id=2684621611","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684621611?lang=zh_cn&edition=full","pubTime":"2026-11-17 08:23","pubTimestamp":1794875033,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0183","BK0187","BK0060","BK0196","BK0239","BK0096","600196","BK0175","BK0188","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684418736","title":"股市必读:复星医药新发布《复星医药关于控股子公司药品获新纳入国家医保目录的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2684418736","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684418736?lang=zh_cn&edition=full","pubTime":"2026-11-17 01:25","pubTimestamp":1794849913,"startTime":"0","endTime":"0","summary":"复星医药关于控股子公司药品临床试验进展的公告FXR0906注射液用于治疗高甘油三酯血症在中国境内启动II期临床试验。复星医药关于控股子公司药品获临床试验批准的公告注射用HLX105获准开展晚期/转移性实体瘤I期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111700000969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK1191","BK0187","02196","BK0239","BK0183","BK0188","BK0028","BK0096","BK0175","BK0060","BK1515","BK1593","600196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683690977","title":"复星医药(02196): FXR0906 注射液用于治疗高甘油三酯血症于中国境内启动 II 期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2683690977","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683690977?lang=zh_cn&edition=full","pubTime":"2026-11-16 18:03","pubTimestamp":1794823397,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)公布,近日,公司控股子公司复星医药产业发展(深圳)有限公司就 FXR0906 注射液用于治疗高甘油三酯血症于中国境内启动 II 期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","PSYK","BMED","BK1593","BK0175","BK0096","BK1515","BK0239","BK0187","BK0028","IBBJ","IBBQ","BK0012","600196","BK0188","MDTX","BK0060","02196","BK1191","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683870692","title":"复星医药(600196.SH)控股子公司药品SRT-003-1获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2683870692","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683870692?lang=zh_cn&edition=full","pubTime":"2026-11-16 17:10","pubTimestamp":1794820205,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药 发布公告,近日,公司控股子公司成都星睿菁烜生物科技有限公司收到国家药品监督管理局关于同意[ 18F]F-SR031 注射液用于实体瘤患者成纤维细胞活化蛋白阳性病灶正电子发射断层扫描显像的临床试验批准。星睿菁烜拟于条件具备后于中国境内开展该药品的 I 期临床研究。以氟[ 18F]标记的FAP抑制剂可与 CAF 表面的 FAP 特异性结合,使 FAP 高表达的肿瘤病灶在PET 显像中呈高摄取,从而用于肿瘤的诊断、分期及疗效评估。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0239","BK0187","BK0060","02196","BK1191","BK1515","BK1593","BK0028","BK0175","BK0188","BK0012","BMED","PSYK","BK0096","IBBQ","IBBJ","MDTX","600196","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683869178","title":"复星医药:控股子公司药品HLX105获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2683869178","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683869178?lang=zh_cn&edition=full","pubTime":"2026-11-16 16:47","pubTimestamp":1794818861,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02196","BK0175","BK0187","BK1515","BK0060","BK0183","600196","BK1593","BK0096","BK0188","BK0012","BK0196","BK1191","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683655437","title":"复星医药:多款药品新纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683655437","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683655437?lang=zh_cn&edition=full","pubTime":"2026-11-15 16:02","pubTimestamp":1794729757,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0183","BK1191","BK1593","BK1515","BK0175","BK0188","02196","BK0028","BK0096","BK0060","BK0012","BK0187","BK0196","600196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683798375","title":"复星医药(02196)11月13日斥资2458.98万港元回购148.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2683798375","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683798375?lang=zh_cn&edition=full","pubTime":"2026-11-13 17:45","pubTimestamp":1794563144,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,于2026年11月13日斥资2458.98万港元回购148.55万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1522974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK0060","BK0239","BK0028","BK0183","BK0175","BK0187","BK0188","BK0012","BK0196","BK1515","BK1593","600196","BK1191","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683576050","title":"复星医药:计划回购H股不超过港币10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2683576050","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683576050?lang=zh_cn&edition=full","pubTime":"2026-11-13 17:39","pubTimestamp":1794562768,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药(600196)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司有考虑增持回购计划吗?谢谢复星医药回复:投资者您好!经董事会批准,公司计划自2026年8月27日起12个月内、以不超过港币10亿元的总金额回购公司H股,回购股份的用途包括但不限于依法注销或作为库存股持有。截至11月13日收市,公司已根据前述回购方案累计回购1,945.40万股H股,累计回购金额约为港币3.28亿元。公司将根据市场情况、股价表现及相关规则,推进上述回购计划。感谢您对公司的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300031294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","600196","BK1191","BK0183","BK0196","BK0096","BK0028","BK0239","BK1515","BK0175","BK0060","BK1593","BK0012","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683457609","title":"复星医药:二级市场股价受公司经营、行业发展、市场情绪、宏观环境等多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2683457609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683457609?lang=zh_cn&edition=full","pubTime":"2026-11-13 17:39","pubTimestamp":1794562749,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药(600196)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问:问公司管理层股价、成交量长期低迷,投资几年一直亏损。你们拿什么回报投资者?对得起中小投资者吗?复星医药回复:投资者您好!二级市场股价受公司经营、行业发展、市场情绪、宏观环境等多重因素影响。公司将持续提升经营质量,努力以更好的经营成果回报投资者。感谢您长期以来的关注与支持。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300031273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","600196","BK0196","BK1515","BK1593","BK0028","BK0096","BK0188","BK0060","BK0183","BK0012","BK0175","BK0187","02196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1795331237186,"stockEarnings":[{"period":"1week","weight":-0.099},{"period":"1month","weight":-0.1193},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.1175},{"period":"1year","weight":-0.2433},{"period":"ytd","weight":-0.2204}],"compareEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.0483},{"period":"3month","weight":-0.0951},{"period":"6month","weight":-0.1408},{"period":"1year","weight":-0.1011},{"period":"ytd","weight":-0.1096}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务,并通过参股国药控股覆盖到医药商业领域。公司的主要产品是注射用曲妥珠单抗(中国境内商品名:汉曲优)及曲妥珠单抗原液、汉利康(利妥昔单抗注射液)、斯鲁利单抗注射液(中国境内商品名:汉斯状)、奥康泽(奈妥匹坦帕洛诺司琼胶囊)、奕凯达(阿基仑赛注射液)、一心坦(沙库巴曲缬沙坦钠片)、汉贝泰(贝伐珠单抗注射液)、汉奈佳(马来酸奈拉替尼片)、倍稳(盐酸凯普拉生片)、珮金(拓培非格司亭注射液)、苏可欣(马来酸阿伐曲泊帕片)、汉达远(阿达木单抗注射液)、普瑞尼(普托马尼片)、达希斐(注射用A型肉毒毒素)、复可舒(抗人T细胞兔免疫球蛋白)、复迈宁(芦沃美替尼片)、欧泰乐(阿普米司特片)、地舒单抗注射液、复妥宁(枸橼酸伏维西利胶囊)、汉倍优(帕妥珠单抗注射液)、万缇乐(盐酸替那帕诺片)、旁必福(盐酸依特卡肽注射液)。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}